Search results
Results from the WOW.Com Content Network
Prostate-specific antigen. Prostate-specific antigen (PSA) is secreted by the epithelial cells of the prostate gland and can be detected in a sample of blood. [14] PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders. [15]
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
The PSA prepayment model is a prepayment scale developed by the Public Securities Association in 1985 for analyzing American mortgage-backed securities. The PSA model assumes increasing prepayment rates for the first 30 months after mortgage origination and a constant prepayment rate thereafter. [ 1 ]
No screening test is wholly specific, and a high level of tumor marker can still be found in benign tumors. The only tumor marker currently used in screening is PSA (prostate-specific antigen). Diagnostics; Tumor markers alone can't be used for diagnostic purposes, due to lack of sensitivity and specificity. [5]
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Missing photographer Hannah Kobayashi may have been intertwined in an alleged marriage scam with an Argentinian national before her disappearance, according to a shocking report.. Kobayashi, 30 ...
From January 2008 to December 2012, if you bought shares in companies when Douglas N. Daft joined the board, and sold them when he left, you would have a 43.9 percent return on your investment, compared to a -2.8 percent return from the S&P 500.
From April 2009 to December 2012, if you bought shares in companies when Michael E. O’Neill joined the board, and sold them when he left, you would have a 22.1 percent return on your investment, compared to a 67.8 percent return from the S&P 500.